Interferon-β therapy prolongs survival in rhesus macaque models of Ebola and Marburg hemorrhagic fever.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 23255566.
- Also identified by DOI 10.1093/infdis/jis921 and PMC identifier 3685222.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
There is a clear need for novel, effective therapeutic approaches to hemorrhagic fever due to filoviruses. Ebola virus hemorrhagic fever is associated with robust interferon (IFN)-α production, with plasma concentrations of IFN-α that greatly (60- to 100-fold) exceed those seen in other viral infections, but little IFN-β production. While all of the type I IFNs signal through the same receptor complex, both quantitative and qualitative differences in biological activity are observed after stimulation of the receptor complex with different type I IFNs. Taken together, this suggested potential for IFN-β therapy in filovirus infection. Here we show that early postexposure treatment with IFN-β significantly increased survival time of rhesus macaques infected with a lethal dose of Ebola virus, although it failed to alter mortality. Early treatment with IFN-β also significantly increased survival time after Marburg virus infection. IFN-β may have promise as an adjunctive postexposure therapy in filovirus infection.
Medical subject headings
- Hemorrhagic Fever, Ebola
- Interferon-beta
- Marburg Virus Disease
- Marburgvirus